Celltrion acquires substance patent of Herceptin biobetter

Celltrion acquired a patent of the Antibody-Drug Conjugate(ADC) substance, a new drug treating breast cancer, from the Korean Intellectual Property Office on the 18^th.

The patent, regarding its manufacturing method and anticancer composition making it active, is a patent for a Herceptin biobetter which maximized its efficacy through combining CT-P6, a biobetter antibody of Herceptin developed ...